Genmab A/S (NASDAQ:GMAB) Sees Unusually-High Trading Volume - What's Next?

Genmab A/S (NASDAQ:GMAB - Get Free Report) saw unusually-strong trading volume on Monday . Approximately 345,719 shares were traded during trading, a decline of 44% from the previous session's volume of 620,495 shares.The stock last traded at $22.69 and had previously closed at $22.98.

Analyst Ratings Changes

Several research firms recently commented on GMAB. BTIG Research raised their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a "buy" rating in a report on Thursday, June 27th. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Genmab A/S in a research report on Tuesday, August 20th. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a report on Wednesday, October 16th. Morgan Stanley restated an "equal weight" rating and issued a $31.00 target price on shares of Genmab A/S in a research note on Wednesday, September 11th. Finally, Redburn Atlantic began coverage on Genmab A/S in a research report on Tuesday, October 8th. They set a "buy" rating on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $45.20.

Genmab A/S Price Performance

The business's 50 day moving average is $25.66 and its two-hundred day moving average is $27.01. The firm has a market capitalization of $15.06 billion, a PE ratio of 18.98, a P/E/G ratio of 0.71 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The company had revenue of $779.50 million during the quarter, compared to analysts' expectations of $734.60 million. Analysts expect that Genmab A/S will post 1.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. raised its position in Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company's stock worth $28,000 after purchasing an additional 544 shares during the period. GAMMA Investing LLC lifted its stake in shares of Genmab A/S by 194.0% in the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company's stock valued at $34,000 after acquiring an additional 749 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in Genmab A/S during the 1st quarter valued at about $43,000. Blue Trust Inc. grew its position in Genmab A/S by 892.0% during the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock worth $108,000 after acquiring an additional 3,880 shares during the last quarter. Finally, Headlands Technologies LLC increased its stake in Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company's stock worth $129,000 after purchasing an additional 4,853 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.